# US 2024/0294895 A1 · Enzymatic compositions for carbohydrate antigen cleavage on donor organs, methods and uses associated therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0294895 A1
- Document ID: US20240294895A1
- Status: Published application
- Kind: A1
- Application number: 18/441,770
- Filed: 2024-02-14
- Published: 2024-09-05
- Earliest claimed: 2018-08-17
- Assignees: The University of British Columbia; University Health Network
- Applicants: The University of British Columbia; University Health Network
- Inventors: Marcelo CYPEL; Aizhou WANG; Shafique KESHAVJEE; Stephen G. WITHERS; Peter RAHFELD; Jayachandran KIZHAKKEDATHU
- Web page: https://patentgrep.com/patent/US20240294895A1

## CPC

- C12N 9/80: acting on amide bonds in linear amides {(3.5.1)}
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 38/54: Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 11/00: Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12Y 302/01049: Alpha-N-acetylgalactosaminidase (3.2.1.49)
- C12Y 305/01025: N-Acetylglucosamine-6-phosphate deacetylase (3.5.1.25)
- C07K 2319/00: Fusion polypeptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods. uses. associated therewith. In particular, the perfusion fluids comprise two enzymes. GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore. the compositions described herein were found to have activity at temperatures and ph levels suitable for cell viability.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A method for enzymatically cleaving A-antigens ex vivo from a donor organ, the method comprising:
(a) perfusing a donor organ displaying type A antigen with a fluid comprising GalNAcDeacetylase protein and a Galactosaminidase protein for a period of time sufficient to allow the enzymes to cleave A-antigens from the donor organ; or
(b) incubating a donor organ displaying type A antigen with a fluid comprising GalNAcDeacetylase protein and a Galactosaminidase protein for a period of time sufficient to allow the enzymes to cleave A-antigens from the donor organ,
wherein the GalNAcDeacetylase protein, the Galactosaminidase protein, or both the GalNAcDeacetylase protein and the Galactosaminidase protein is derived from Flavonifractor plautii.

### Claim 12 (depends on 11)

The method of claim 11, wherein the GalNAcDeacetylase protein comprises a polypeptide sequence selected from SEQ ID NO.: 2; SEQ ID NO.: 4; SEQ ID NO.: 5; and the Galactosaminidase protein comprises a polypeptide sequence selected from: SEQ ID NO.: 7; SEQ ID NO.: 9; SEQ ID NO.: 10.

### Claim 13 (depends on 11)

The method of claim 11, wherein the composition comprises: a GalNAcDeacetylase protein comprising a polypeptide sequence at least 90% identical to the sequence set forth in one of SEQ ID NOs: 2, 4, and 5; and a Galactosaminidase protein comprising a polypeptide sequence at least 90% identical to the sequence set forth in one of SEQ ID NOs: 7, 9, and 10.

### Claim 14

(canceled)

### Claim 15 (depends on 11)

The method of claim 11, wherein the GalNAcDeacetylase protein and the Galactosaminidase protein are in a buffered extracellular solution.

### Claim 16 (depends on 15)

The method of claim 15, wherein the buffered extracellular solution is selected from: EuroCollins solution; Histidine-Tryptophan-Ketoglutarate (HTK) solution; Celsior solution; Kidney Perfusion solution (KPS-1); and Citrate solution.

### Claim 17 (depends on 11)

The method of claim 11, wherein the donor organ is a solid organ.

### Claim 18 (depends on 17)

The method of claim 17, wherein the solid organ is selected from one of the following: lung; kidney; liver; heart; pancreas; and intestine.

### Claim 19 (depends on 17, 18)

The method of claim 18, wherein the solid organ is a lung. 20 (Currently Amended) The method of claim 17, wherein the solid organ is a lung, and the GalNAcDeacetylase protein and the Galactosaminidase protein is mixed with an ex vivo buffered extracellular lung solution and circulated through the lung, whereby the GalNAcDeacetylase protein and the Galactosaminidase protein are in contact with the vasculature of the donor organ for a period of time sufficient to substantially clear the A-antigens from the vasculature of the lung.

### Claim 21 (depends on 20)

The method of claim 20, wherein the period of time sufficient to substantially clear the A-antigens from the vasculature of the lung is about 1 hour.

### Claim 22 (depends on 11)

The method of claim 11, wherein the method further comprises washing the donor organ to remove GalNAcDeacetylase protein, Galactosaminidase protein and cleaved A-antigens.

### Claim 23 (depends on 11)

The method of claim 11, wherein the GalNAcDeacetylase protein and Galactosaminidase protein are capable of cleaving A-antigen at or below 1 μg/ml.

### Claim 24 (depends on 11)

The method of claim 11, wherein the GalNAcDeacetylase protein and Galactosaminidase protein have A-antigen cleaving activity at a pH between about 6.5 and about 7.5.

### Claim 25 (depends on 11)

The method of claim 11, wherein the GalNAcDeacetylase protein and Galactosaminidase protein have A-antigen cleaving activity at a temperatures between 4° C. and 37° C.

### Claim 26 (depends on 17)

The method of claim 17, wherein the solid organ is a kidney, and the GalNAcDeacetylase protein and the Galactosaminidase protein is mixed with an ex vivo buffered extracellular kidney solution and circulated through the kidney, whereby the GalNAcDeacetylase protein and the Galactosaminidase protein are in contact with the vasculature of the donor organ for a period of time sufficient to substantially clear the A-antigens from the vasculature of the kidney.

### Claim 27 (depends on 26)

The method of claim 26, wherein the period of time sufficient to substantially clear the A-antigens from the vasculature of the kidney is about 1 hour.

### Claim 28 (depends on 26)

The method of claim 26, wherein the method further comprises washing the donor organ to remove GalNAcDeacetylase protein, Galactosaminidase protein and cleaved A-antigens.

### Claim 29 (depends on 15)

The method of claim 15, wherein the buffered extracellular solution includes a crowding agent.
